You are here

ASCO 2023

Merck and Eisai tease results for renal carcinoma treatment

Merck and Eisai tease results for renal carcinoma treatment

Clinical Trials Arena

renal cell carcinoma

Flag link:

Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023

Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023

BioSpace

Hummingbird Biosciences

cliincal trials

triple-negative breast cancer

non-small cell lung cancer

Flag link:

AstraZeneca's drug combo shows positive results in late-stage cancer trial

AstraZeneca's drug combo shows positive results in late-stage cancer trial

Reuters

endometrial cancer

Flag link:

ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?

ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?

Fierce Pharma

Bristol Myers Squibb

clinical trials

Flag link:

ASCO puts spotlight on advancing antibody-drug conjugate pipeline

ASCO puts spotlight on advancing antibody-drug conjugate pipeline

BioPharma Dive

antibody-drug conjugate

Flag link:

ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma

ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma

Fierce Biotech

advanced melanoma

Flag link:

ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA change its mind?

ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA change its mind?

Fierce Pharma

cervical cancer

Flag link:

ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers

ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers

Fierce Pharma

non-small cell lung cancer

early breast cancer

Flag link: